Physician profile
Hui Wu
NPI 1790039311
$7,462.64
in general payments reported to CMS, 2019-2025
21 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,347 · 2022: $1,480 · 2023: $1,451 · 2024: $1,448 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,635.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,850.69 | 2021-2025 | |
| Gilead Sciences, INC. | $2,267.89 | 2021-2025 | Livdelzi, Epclusa, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $783.48 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $449.68 | 2022-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $264.84 | 2025 | Rezdiffra |
| Ardelyx, INC. | $158.56 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $129.09 | 2021-2025 | |
| Ibsa Pharma INC. | $116.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $72.96 | 2024-2025 | Voquezna |
| Intra-Sana Laboratories | $56.55 | 2022 | |
| Braintree Laboratories, INC. | $54.96 | 2021-2023 | Suflave, Sutab |
| Redhill Biopharma INC. | $54.72 | 2021 | |
| Pfizer INC. | $48.34 | 2023 | |
| Ironwood Pharmaceuticals, INC | $33.43 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $23.04 | 2025 | Iqirvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.77 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $17.18 | 2024 | Trelegy Ellipta |
| Qol Medical, LLC | $16.97 | 2023 | Sucraid |
| W. L. Gore & Associates, INC. | $16.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2023 | Gattex |
| Vivus LLC | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.